Skip to main content
OpenTrials
Completed

NCT Number: NCT03408054

The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium

Oxytocin causes myometrial contraction via the oxytocin receptor (OTR). Desensitization of the OTR after exposure to oxytocin has been demonstrated in previous studies. The resultant need for a higher oxytocin dose to cause adequate uterine contraction in vivo has also been demonstrated in laboring women having received oxytocin for labor augmentation.

Achieving rapid uterine relaxation can be invaluable for maternal and fetal wellbeing in some acute obstetric emergency settings. Nitroglycerin has become a commonly used agent for achieving rapid uterine relaxation amongst obstetric anesthesiologists.

Previous studies have concluded that oxytocin can be used to re-establish uterine tone following nitroglycerin mediated relaxation. However, no studies to date have looked at the effects of nitroglycerin mediated relaxation of uterine muscle that has undergone oxytocin receptor desensitization. Nor has the response to oxytocin re-exposure and return of contractility in desensitized myometrium (following nitroglycerin) been examined.

The investigators hypothesize that nitroglycerin will reduce and inhibit uterine contractions in both oxytocin pre-treated myometrium, as well as untreated myometrium in a dose dependent fashion, but that myometrium that has undergone OTR desensitization will require less nitroglycerin for contractions to abate.

The investigators also expect that the dose of oxytocin required to re-establish equivalent contractions will be higher in the myometrial samples which have undergone nitroglycerin mediated relaxation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postpartum Hemorrhage Female Urogenital Diseases and Pregnancy Complications Hemorrhage Obstetric Labor Complications Pathologic Processes Pathological Conditions, Signs and Symptoms Pregnancy Complications Puerperal Disorders Urogenital Diseases Uterine Hemorrhage

Age range

16 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mount Sinai Hospital

Toronto, Ontario, M5G1X5, Canada

About this study

Oxytocin and nitroglycerin have opposing actions on the myometrium. The pharmacological properties of quick onset and offset of action of nitroglycerin have made this the preferred drug to be used in acute scenarios where uterine relaxation is necessary.

As nitroglycerin causes changes to intracellular calcium levels and the ability uterine muscle to engage in effective contraction, it is plausible that the effects of nitroglycerin may interfere with subsequent uterine contractility and action of oxytocin.

The situation where a difficult fetal extraction is encountered at cesarean section may be in two broad groups of patients. Those pre-exposed to oxytocin and those with an oxytocin naïve myometrium. Given the large observational variation in dosages of nitroglycerin usage seen in the literature we feel it is vital to investigate whether pre-exposure to oxytocin impacts on the ability of nitroglycerin to relax uterine smooth muscle. Furthermore, once the uterus has relaxed following nitroglycerin exposure, is there a need for higher doses of oxytocin to be administered in order to re-engage the uterus in effective contraction? And is this requirement further exacerbated by the phenomenon of oxytocin receptor desensitization? These clinically important questions will be addressed by the design of this in vitro myometrial study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who give written consent to participate in this study
  • Patients with gestational age 37-41 weeks
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring primary Cesarean delivery or first repeat Cesarean delivery under spinal anesthesia

Exclusion criteria

  • Patients who refuse to give written informed consent
  • Patients who require general anesthesia
  • Patients who had previous uterine surgery or more than one previous Cesarean delivery
  • Patients with any condition predisposing to uterine atony and postpartum hemorrhage, such as abnormal placentation, multiple gestation, preeclampsia, macrosomia, polyhydramnios, uterine fibroids, bleeding diathesis, chorioamnionitis, or a previous history of postpartum bleeding
  • Emergency Cesarean section in labor
  • Patients with medical/pregnancy related conditions, such as diabetes, preeclampsia and essential hypertension

Treatment and study plan

Oxytocin

Drug

Oxytocin 10-5M solution

Other names: Duratocin, pitocin

Nitroglycerin

Drug

Nitroglycerin 25-1000mcg

Primary outcomes

  1. Motility Index

    Time frame: 8 hours

    Motility index (MI) takes into account both the amplitude and frequency of the myometrial contraction. It is a calculated outcome, based on the formula: frequency/(10 x amplitude).

    The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

Secondary outcomes

  1. Amplitude of contraction

    Time frame: 8 hours

    The maximum extent of uterine muscle contraction, measured in grams (g). The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

  2. Frequency of contraction

    Time frame: 8 hours

    The number of contractions in uterine muscle (myometrium) over 10 minutes, spontaneously and in response to an agonist.

    The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

  3. Integrated area under response curve (AUC)

    Time frame: 8 hours

Sponsors and collaborators

Lead sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Other

Registry information

Official study title

The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium and the Return of Contractility on Re-exposure to Oxytocin- an in Vitro Study

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 23, 2018
Registry last updated
Feb 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.